皮肤鳞状细胞癌诊疗专家共识（2021）

doi:10.35541/cjd.20201140

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (8): 653-664.doi: 10.35541/cjd.20201140

皮肤鳞状细胞癌诊疗专家共识（2021）

中华医学会皮肤性病学分会皮肤肿瘤研究中心中国医师协会皮肤科医师分会皮肤肿瘤学组

中华医学会皮肤性病学分会皮肤肿瘤研究中心中国医师协会皮肤科医师分会皮肤肿瘤学组

收稿日期:2020-11-29 修回日期:2021-05-04 发布日期:2021-08-02
通讯作者: 陈翔,耿松梅 E-mail:chenxiangck@126.com;gsm312@yahoo.com

Consensus on diagnosis and treatment of cutaneous squamous cell carcinoma （2021）

Skin Tumor Research Center, Chinese Society of Dermatology; Subcommittee on Skin Tumor, China Dermatologist Association

Skin Tumor Research Center, Chinese Society of Dermatology; Subcommittee on Skin Tumor, China Dermatologist Association

Received:2020-11-29 Revised:2021-05-04 Published:2021-08-02
Contact: Chen Xiang; Geng Songmei E-mail:chenxiangck@126.com;gsm312@yahoo.com

摘要/Abstract

摘要： 【摘要】皮肤鳞状细胞癌是非黑素瘤皮肤癌中最常见的肿瘤之一。近年来随着对其发病机制研究的深入以及诊断技术、Mohs显微描记手术、靶向治疗、免疫治疗的发展，皮肤鳞状细胞癌的诊疗取得了较大进展。该共识在国内外近期文献及诊疗指南的基础上，结合我国的诊疗现状，重点阐述皮肤鳞状细胞癌的临床表现及分型、病理活检及报告规范、风险等级评估、分级分期以及规范化治疗等，为临床医生的诊疗工作提供参考依据。

关键词: 肿瘤, 鳞状细胞, 皮肤, 诊断, 临床方案, 专家共识

Abstract: 【Abstract】 Cutaneous squamous cell carcinoma （cSCC） is one of the most common non-melanoma skin cancers. In recent years, with the in-depth study of its pathogenesis, as well as the development of diagnostic technology, Mohs micrographic surgery, targeted therapy and immunotherapy, great progress has been made in the diagnosis and treatment of cSCC. Based on recent domestic and international relevant literature and guidelines, and combined with the availability of diagnostic and therapeutic methods in China, this consensus focuses on clinical manifestations, classification, biopsy pathology and report standards, risk factor assessment, grading, staging, and standardized treatment of cSCC, and aims to provide a reference for the diagnosis and treatment of cSCC in clinical practice.

Key words: Neoplasms, squamous cell, Skin, Diagnosis, Clinical protocols, Expert consensus

中华医学会皮肤性病学分会皮肤肿瘤研究中心中国医师协会皮肤科医师分会皮肤肿瘤学组. 皮肤鳞状细胞癌诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021,54(8):653-664. doi:10.35541/cjd.20201140

Skin Tumor Research Center, Chinese Society of Dermatology, Subcommittee on Skin Tumor, China Dermatologist Association. Consensus on diagnosis and treatment of cutaneous squamous cell carcinoma （2021）[J]. Chinese Journal of Dermatology, 2021, 54(8): 653-664.doi:10.35541/cjd.20201140

参考文献 77

［1］	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability⁃adjusted life⁃years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study［J］. JAMA Oncol, 2017,3（4）:524⁃548. doi: 10.1001/jamaoncol. 2016.5688.
［2］	GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016［J］. Lancet, 2018,391（10136）:2236⁃2271. doi: 10.1016/S0140⁃6736（18）30994⁃2.
［3］	National Comprehensive Cancer Network. Squamous cell skin cancer, version 1.2021, NCCN clinical practice guidelines in oncology［Z/OL］. （2021⁃02⁃05）［2021⁃04⁃07］. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
［4］	Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. Epidemiology, diagnostics and prevention［J］. Eur J Cancer, 2020,128:60⁃82. doi: 10.1016/j.ejca.2020.01.007.
［5］	Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment［J］. Eur J Cancer, 2020,128:83⁃102. doi: 10.1016/j.ejca.2020.01.008.
［6］	Elder DE, Massi D, Scolyer RA, et al. WHO classification of skin tumours［M］. 4th ed. Lyon:IARC Press, 2018:470.
［7］	国务院人口普查办公室, 国家统计局人口和就业统计司. 中国2010年人口普查资料［M］. 北京: 中国统计出版社, 2012:265. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm.
［8］	涂庆峰, 吕婷, 赖永贤, 等. 上海市某社区老年人皮肤肿瘤流行病学研究［J］. 老年医学与保健, 2013,19（3）:142⁃145,148. doi: 10.3969/j.issn.1008⁃8296.2013⁃05.
［9］	高天文, 孙东杰, 李春英, 等. 中国西部两医院1905例皮肤恶性肿瘤回顾分析［J］. 北京大学学报（医学版）, 2004,36（5）:469⁃472. doi: 10.3321/j.issn:1671⁃167X.2004.05.005.
［10］	Wikonkal NM, Brash DE. Ultraviolet radiation induced signature mutations in photocarcinogenesis［J］. J Investig Dermatol Symp Proc, 1999,4（1）:6⁃10. doi: 10.1038/sj.jidsp.56 40173.
［11］	Lindelöf B, Sigurgeirsson B, Gäbel H, et al. Incidence of skin cancer in 5356 patients following organ transplantation［J］. Br J Dermatol, 2000,143（3）:513⁃519.
［12］	Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long⁃term immunosuppressive therapy regimens［J］. J Am Acad Dermatol, 1999,40（2 Pt 1）:177⁃186. doi: 10.1016/s0190⁃9622（99）70185⁃4.
［13］	Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in the Netherlands［J］. Transplantation, 1990,49（3）:506⁃509. doi: 10.1097/00007890⁃199003000⁃00006.
［14］	Bolognia JL, Schaffer JV, Cerroni L. 皮肤病学［M］. 朱学骏, 王宝玺, 孙建方, 等, 译. 4版. 北京: 北京大学医学出版社, 2019:2077⁃2079.
［15］	Zhao H, Shu G, Wang S. The risk of non⁃melanoma skin cancer in HIV⁃infected patients: new data and meta⁃analysis［J］. Int J STD AIDS, 2016,27（7）:568⁃575. doi: 10.1177/095646241558 6316.
［16］	Torchia D, Massi D, Caproni M, et al. Multiple cutaneous precanceroses and carcinomas from combined iatrogenic/professional exposure to arsenic［J］. Int J Dermatol, 2008,47（6）:592⁃593. doi: 10.1111/j.1365⁃4632.2008.03547.x.
［17］	Yuspa SH. Cutaneous chemical carcinogenesis［J］. J Am Acad Dermatol, 1986,15（5 Pt 1）:1031⁃1044. doi: 10.1016/s0190⁃9622 （86）70267⁃3.
［18］	Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma［J］. J Clin Invest, 2012,122（2）:464⁃472. doi: 10.1172/JCI57415.
［19］	Harwood CA, Proby CM, Inman GJ, et al. The promise of genomics and the development of targeted therapies for cutaneous squamous cell carcinoma［J］. Acta Derm Venereol, 2016,96（1）:3⁃16. doi: 10.2340/00015555⁃2181.
［20］	Di Nardo L, Pellegrini C, Di Stefani A, et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies［J］. J Eur Acad Dermatol Venereol, 2020,34（5）:932⁃941. doi: 10.1111/jdv.16098.
［21］	Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV⁃induced p53 mutations in squamous cell carcinoma［J］. Proc Natl Acad Sci U S A, 1991,88（22）:10124⁃10128. doi: 10.1073/pnas.88.22.10124.
［22］	South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis［J］. J Invest Dermatol, 2014,134（10）:2630⁃2638. doi: 10.1038/jid. 2014.154.
［23］	Wang NJ, Sanborn Z, Arnett KL, et al. Loss⁃of⁃function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma［J］. Proc Natl Acad Sci U S A, 2011,108（43）:17761⁃17766. doi: 10.1073/pnas.1114669108.
［24］	Lee CS, Bhaduri A, Mah A, et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma［J］. Nat Genet, 2014,46（10）:1060⁃1062. doi: 10.1038/ ng.3091.
［25］	Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma［J］. Curr Opin Oncol, 2011,23（2）:177⁃182. doi: 10.1097/CCO.0b013e3283436e8c.
［26］	Li YY, Hanna GJ, Laga AC, et al. Genomic analysis of metastatic cutaneous squamous cell carcinoma［J］. Clin Cancer Res, 2015,21（6）:1447⁃1456. doi: 10.1158/1078⁃0432.CCR⁃14⁃1773.
［27］	Uribe P, Gonzalez S. Epidermal growth factor receptor （EGFR） and squamous cell carcinoma of the skin: molecular bases for EGFR⁃targeted therapy［J］. Pathol Res Pract, 2011,207（6）:337⁃342. doi: 10.1016/j.prp.2011.03.002.
［28］	Asgari MM, Toland AE, Arron ST. IRF4 polymorphism is associated with cutaneous squamous cell carcinoma in organ transplant recipients: a pigment⁃independent phenomenon［J］. J Invest Dermatol, 2017,137（1）:251⁃253. doi: 10.1016/j.jid.2016. 07.038.
［29］	Chahal HS, Lin Y, Ransohoff KJ, et al. Genome⁃wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma［J］. Nat Commun, 2016,7:12048. doi: 10.1038/ncomms12048.
［30］	Asgari MM, Wang W, Ioannidis NM, et al. Identification of susceptibility loci for cutaneous squamous cell carcinoma［J］. J Invest Dermatol, 2016,136（5）:930⁃937. doi: 10.1016/j.jid.2016. 01.013.
［31］	Sarin KY, Lin Y, Daneshjou R, et al. Genome⁃wide meta⁃analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma［J］. Nat Commun, 2020,11（1）:820. doi: 10.1038/s41467⁃020⁃14594⁃5.
［32］	Boateng B, Hornstein OP, von den Driesch P, et al. Multiple keratoacanthomas （Witten⁃Zak type） in prurigo simplex subacuta［J］. Hautarzt, 1995,46（2）:114⁃117. doi: 10.1007/s001 050050219.
［33］	张聪聪, 陈浩. Muir⁃Torre综合征的研究进展［J］. 中国麻风皮肤病杂志, 2020,36（4）:253⁃256. doi: 10.12144/zgmfskin20200 4253.
［34］	国家皮肤与免疫疾病临床医学研究中心, 中国医师协会皮肤科医师分会皮肤外科亚专业委员会, 中国中西医结合学会皮肤性病学专业委员会皮肤影像学组, 等. 常见皮肤病高频皮肤超声诊断专家共识［J］. 中国医学前沿杂志（电子版）, 2019,11（8）:23⁃28. doi: 10.12037/YXQY.2019.08⁃04.
［35］	中国中西医结合学会皮肤性病学分会皮肤影像学组. 常见非黑素细胞性皮肤肿瘤皮肤镜特征与组织病理表现的对应关系专家共识［J］. 中华皮肤科杂志, 2021,54（1）:10⁃18. doi: 10.35541/cjd.20200446.
［36］	高天文, 王雷, 廖文俊. 实用皮肤组织病理学［M］. 2版. 北京: 人民卫生出版社, 2018:701.
［37］	Henderson SA, Torres⁃Cabala CA, Curry JL, et al. p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies［J］. Am J Surg Pathol, 2014,38（8）:1102⁃1110. doi: 10.1097/PAS.0000000000 000245.
［38］	Bice TC, Tran V, Merkley MA, et al. Disease⁃specific survival with spindle cell carcinoma of the head and neck［J］. Otolaryngol Head Neck Surg, 2015,153（6）:973⁃980. doi: 10. 1177/0194599815594360.
［39］	Fu JM, McCalmont T, Yu SS. Adenosquamous carcinoma of the skin: a case series［J］. Arch Dermatol, 2009,145（10）:1152⁃1158. doi: 10.1001/archdermatol.2009.218.
［40］	Al⁃Arashi MY, Byers HR. Cutaneous clear cell squamous cell carcinoma in situ: clinical, histological and immunohisto⁃chemical characterization［J］. J Cutan Pathol, 2007,34（3）:226⁃233. doi: 10.1111/j.1600⁃0560.2006.00593.x.
［41］	Chung HJ, Wolpowitz D, Scott G, et al. Squamous cell carcinoma with osteoclast⁃like giant cells: a morphologically heterologous group including carcinosarcoma and squamous cell carcinoma with stromal changes［J］. J Cutan Pathol, 2016,43（2）:148⁃157. doi: 10.1111/cup.12607.
［42］	Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus⁃based interdisciplinary guideline［J］. Eur J Cancer, 2015,51（14）:1989⁃2007. doi: 10.1016/j.ejca.2015.06.110.
［43］	Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery［J］. Arch Dermatol, 2002,38（8）:1043⁃1051. doi: 10.1001/ archderm.138.8.1043.
［44］	Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years［J］. J Am Acad Dermatol, 2005,53（2）:253⁃260. doi: 10.1016/j.jaad.2005.02.059.
［45］	Tschetter AJ, Campoli MR, Zitelli JA, et al. Long⁃term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: a 5⁃year, multicenter, prospective cohort study［J］. J Am Acad Dermatol, 2020,82（1）:139⁃148. doi: 10.1016/j.jaad.2019.06.1303.
［46］	张良. Mohs显微描记手术治疗皮肤恶性肿瘤56例临床分析［J］. 中国皮肤性病学杂志, 2012,26（3）:268⁃270.
［47］	Breuninger H, Brantsch K, Eigentler T, et al. Comparison and evaluation of the current staging of cutaneous carcinomas［J］. J Dtsch Dermatol Ges, 2012,10（8）:579⁃586. doi: 10.1111/j.1610⁃0387.2012.07896.x.
［48］	Tejera⁃Vaquerizo A, Cañueto J, Llombart B, et al. Predictive value of sentinel lymph node biopsy in cutaneous squamous cell carcinoma based on the AJCC⁃8 and Brigham and Women′s Hospital Staging Criteria［J］. Dermatol Surg, 2020,46（7）:857⁃862. doi: 10.1097/DSS.0000000000002170.
［49］	Durham AB, Lowe L, Malloy KM, et al. Sentinel lymph node biopsy for cutaneous squamous cell carcinoma on the head and neck［J］. JAMA Otolaryngol Head Neck Surg, 2016,142（12）:1171⁃1176. doi: 10.1001/jamaoto.2016.1927.
［50］	Work Group, Invited Reviewers, Kim J, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma［J］. J Am Acad Dermatol, 2018,78（3）:560⁃578. doi: 10.1016/j.jaad. 2017.10.007.
［51］	Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons［J］. Dermatol Surg, 2013,39（9）:1306⁃1316. doi: 10. 1111/dsu.12300.
［52］	Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review［J］. Arch Dermatol, 2009,145（12）:1431⁃1438. doi: 10.1001/archdermatol.2009.291.
［53］	Lansbury L, Bath⁃Hextall F, Perkins W, et al. Interventions for non⁃metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies［J］. BMJ, 2013,347:f6153. doi: 10.1136/bmj.f6153.
［54］	Zaar O, Fougelberg J, Hermansson A, et al. Effectiveness of photodynamic therapy in Bowen′s disease: a retrospective observational study in 423 lesions［J］. J Eur Acad Dermatol Venereol, 2017,31（8）:1289⁃1294. doi: 10.1111/jdv.14164.
［55］	Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial［J］. Arch Dermatol, 2006,142（6）:729⁃735. doi: 10.1001/archderm.142.6.729.
［56］	葛新红, 焦亚宁, 董灵娣, 等. 5⁃氨基酮戊酸光动力治疗皮肤肿瘤的疗效观察［J］. 中国皮肤性病学杂志, 2015,29（10）:1035⁃1037. doi: 10.13735/j.cjdv.1001⁃7089.201411108.
［57］	Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology Clinical Practice Guideline［J］. Pract Radiat Oncol, 2020,10（1）:8⁃20. doi: 10.1016/j.prro.2019.10.014.
［58］	Ribero S, Stucci LS, Daniels GA, et al. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?［J］. Curr Opin Oncol, 2017,29（2）:129⁃135. doi: 10. 1097/CCO.0000000000000359.
［59］	Guthrie TH Jr, Porubsky ES, Luxenberg MN, et al. Cisplatin⁃based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy［J］. J Clin Oncol, 1990,8（2）:342⁃346. doi: 10.1200/JCO.1990.8.2.342.
［60］	Wollina U, Hansel G, Koch A, et al. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin［J］. J Cancer Res Clin Oncol, 2005,131（5）:300⁃304. doi: 10.1007/s00432⁃004⁃0656⁃6.
［61］	Cartei G, Cartei F, Interlandi G, et al. Oral 5⁃fluorouracil in squamous cell carcinoma of the skin in the aged［J］. Am J Clin Oncol, 2000,23（2）:181⁃184. doi: 10.1097/00000421⁃200004000⁃ 00015.
［62］	Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer［J］. J Clin Oncol, 2002,20（2）:364⁃370. doi: 10.1200/JCO.2002.20.2.364.
［63］	Mecca C, Ponzetti A, Caliendo V, et al. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel［J］. Eur J Dermatol, 2012,22（6）:758⁃761. doi: 10. 1684/ejd.2012.1845.
［64］	Trodello C, Pepper JP, Wong M, et al. Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review［J］. Dermatol Surg, 2017,43（1）:40⁃49. doi: 10. 1097/DSS.0000000000000799.
［65］	Jarkowski A 3rd, Hare R, Loud P, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma （CSCC）: the Roswell Park experience and a review of the literature［J］. Am J Clin Oncol, 2016,39（6）:545⁃548. doi: 10.1097/COC.000000000 0000088.
［66］	Harwood CA, Leedham⁃Green M, Leigh IM, et al. Low⁃dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16⁃year retrospective study［J］. Arch Dermatol, 2005,141（4）:456⁃464. doi: 10.1001/archderm. 141.4.456.
［67］	Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double⁃blind, placebo⁃controlled study［J］. J Clin Oncol, 1995,13（8）:1933⁃1938. doi: 10.1200/JCO.1995.13.8.1933.
［68］	Zhao Y, Zhu Y, Wang H, et al. Case report: successful treatment of cutaneous squamous cell carcinoma in three patients with a combination of acitretin and clarithromycin［J］. Front Oncol, 2021,11:650974. doi: 10.3389/fonc.2021.650974.
［69］	Fox E, Elghobashy M, Hamad H, et al. Oral retinoid, acitretin, is effective in the management of resistant recurrent vulval verrucous carcinoma: a case report［J］. J Obstet Gynaecol Res, 2020,46（10）:2179⁃2184. doi: 10.1111/jog.14390.
［70］	Robertson SJ, Bashir SJ, Pichert G, et al. Severe exacerbation of multiple self⁃healing squamous epithelioma （Ferguson⁃Smith disease） with radiotherapy, which was successfully treated with acitretin［J］. Clin Exp Dermatol, 2010,35（4）:e100⁃e102. doi: 10.1111/j.1365⁃2230.2009.03668.x.
［71］	Yerebakan O, Ermis O, Yilmaz E, et al. Treatment of arsenical keratosis and Bowen′s disease with acitretin［J］. Int J Dermatol, 2002,41（2）:84⁃87. doi: 10.1046/j.1365⁃4362.2002.01372.x.
［72］	Ahmed SR, Petersen E, Patel R, et al. Cemiplimab⁃rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma［J］. Expert Rev Clin Pharmacol, 2019,12（10）:947⁃951. doi: 10.1080/17512433.2019.1665026.
［73］	Foote MC, McGrath M, Guminski A, et al. Phase II study of single⁃agent panitumumab in patients with incurable cutaneous squamous cell carcinoma［J］. Ann Oncol, 2014,25（10）:2047⁃2052. doi: 10.1093/annonc/mdu368.
［74］	Carlson CL. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review［J］. J Pain Res, 2016,9:515⁃534. doi: 10.2147/JPR.S97759.
［75］	Flohil SC, van der Leest RJ, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta⁃analysis［J］. Eur J Cancer, 2013,49（10）:2365⁃2375. doi: 10.1016/j.ejca. 2013.03.010.
［76］	Levine DE, Karia PS, Schmults CD. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10⁃year single⁃institution cohort study［J］. JAMA Dermatol, 2015,151（11）:1220⁃1225. doi: 10.1001/jamadermatol.2015.1702.
［77］	Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous⁃cell carcinoma: a prospective study［J］. Lancet Oncol, 2008,9（8）:713⁃720. doi: 10.1016/S1470⁃2045（08）70178⁃5.

[1]	韩晓锋孙娟邱磊尉莉马琳. 儿童穿通型毛母质瘤29例临床病理特点分析[J]. 中华皮肤科杂志, 2022, 55(3): 196-199.
[2]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
[3]	王晓雯李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275.
[4]	徐聪聪陈浩. PI3K/Akt/mTOR信号通路在皮肤鳞状细胞癌中的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 264-267.
[5]	吕玲吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279.
[6]	李锁向睿宇李志量荆可王媛张寒梅冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237.
[7]	付超吴姣娜郎文超高菲牛贵业边培雯高敏虹司晓青辛琳琳. 皮肤镜检查在评估白癜风疾病活动性中的作用[J]. 中华皮肤科杂志, 2022, 55(3): 268-271.
[8]	王召阳陈安薇向欣罗晓燕徐子刚王华马琳. 基于两家儿童医院信息系统的儿童银屑病现状调查[J]. 中华皮肤科杂志, 2022, 55(3): 246-250.
[9]	岳超, 罗显雁, 王涛, 段梦莹, 戴叶芹, 彭建中. 纵向切口横向缝合法在下眼睑缘五边形全层缺损修复中的应用[J]. 中华皮肤科杂志, 2022, 55(2): 159-161.
[10]	阎诗, 周小英, 罗晓燕, 任发亮, 江为, 牛琳琳, 王华, 白晓明. Spink5基因条件性敲除小鼠模型的构建及表型分析[J]. 中华皮肤科杂志, 2022, 55(2): 95-101.
[11]	葛新红, 焦亚宁, 葛明昊, 马迎东, 石越, 王禹, 刘玲玲. 沉默信息调节因子1、3和缺氧诱导因子1α在皮肤鳞状细胞癌组织和细胞中的表达[J]. 中华皮肤科杂志, 2022, 55(2): 116-122.
[12]	林羽洁, 刘凤洁, 高玉梅, 刘向君, 许卜方, 李映依, 赖盼, 陈卓婧, 孙婧茹, 涂平, 汪旸. 溶血磷脂酸受体6在蕈样肉芽肿向大细胞转变中的意义及其对皮肤T细胞淋巴瘤细胞增殖和凋亡的影响[J]. 中华皮肤科杂志, 2022, 55(2): 102-109.
[13]	王慧, 刘董, 田芳, 魏志平. 表皮生长因子受体shRNA联合西罗莫司对Colo-16细胞体外增殖、凋亡的研究[J]. 中华皮肤科杂志, 2022, 55(2): 135-141.
[14]	高妮, 刘宇, 王雷, 刘玲, 高天文, 李凯. 孤立性真皮黑素瘤5例临床及组织病理分析[J]. 中华皮肤科杂志, 2022, 0(2): 20200775-e20200775.
[15]	张国毅, 龚向东, 朱伯堃, 柳传霞, 景玲华, 徐金玉. 2019年中国医学科学院皮肤病医院门诊病种分析[J]. 中华皮肤科杂志, 2022, 55(2): 150-152.

皮肤鳞状细胞癌诊疗专家共识（2021）

Consensus on diagnosis and treatment of cutaneous squamous cell carcinoma （2021）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 77

相关文章 15

Metrics

本文评价

推荐阅读 10